Treatment of venous thromboembolism with low-molecular-weight heparin: A synthesis of the evidence published in systematic literature reviews

Respiratory Medicine

Volumn 98, Issue 5, 2004, Pages 376-386

  Krishnan, J A ^a,b   Segal, J B ^b   Streiff, M B ^b   Bolger, D T ^b   Eng, J ^b   Jenckes, M W ^b   Tamariz, L J ^b   Bass, E B ^b,c  

^a Johns Hospkins Medical Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Low molecular weight heparin; Systematic reviews; Unfractionated heparin; Venous thromboembolism

Indexed keywords

CERTOPARIN; CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN;

ANALYTIC METHOD; BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

EID: 2342621534     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.02.017     Document Type: Article

References (39)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:14-8.
2. Weitz J. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
3. Cappelleri JC, Ioannidis JP, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? J Am Med Assoc 1996;276:1332-8.
4. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
5. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med 1995;123:873-7.
6. Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. J Am Med Assoc 1998;279:1089-93.
7. Petticrew M, Kennedy SC. Detecting the effects of thromboprophylaxis: the case of the rogue reviews. Br Med J 1997;315:665-8.
8. Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature - VI. How to use an overview. Evidence-based medicine working group. J Am Med Assoc 1994;272: 1367-71.
9. Naylor D. Meta-analysis and meta-epidemiology of clinical research. Br Med J 1997;315:617-9.
10. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Onkologie 2000;23:597-602.
11. Jadad AR, Moher M, Browman GP, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. Br Med J 2000;320:537-40.
12. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Systematic reviews of trials and other studies. Health Technol Assess 1998;2:1-276.
13. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the potsdam consultation on meta-analysis. J Clin Epidemiol 1995;48:167-71.
14. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991;44:1271-8.
15. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-anatyses of randomized controlled trials. N Engl J Med 1987;316:450-5.
16. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW. Low-molecular-weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
17. Hettiarachchi RJ, Prins MH, Lensing AW, Buller HR. Low-molecular-weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998;4:220-5.
18. Howard PA. Dalteparin: a tow-molecular-weight heparin. Ann Pharmacother 1997;31:192-203.
19. Hunt D. Low-molecular-weight heparins in clinical practice. South Med J 1998;91:2-10.
20. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998;32:588-98 (review: 601).
21. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130: 789-99.
22. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8.
23. Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low-molecular-weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Hoematologica 2000;85:935-42.
24. van Den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low-molecular-weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000;CD001100.
25. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low-molecular-weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74:360-3.
26. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.
27. Leizorovicz A. Comparison of the efficacy and safety of low-molecular-weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis. Drugs 1996;52:30-7.
28. Brewer D. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis? J Fam Pract 1998;47:185-92.
29. van der Heijden J, Prins M, Buller H. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 2000;100:V121-30.
30. Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thromb Haemost 2000;83:652-6.
31. Mulrow CD, Oxman AD. Cochrane collaboration handbook. Cochrane Database Syst Rev 1998.
32. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351:47-52.
33. Villar J, Mackey ME, Carroli G, Donner A. Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: a comparison of fixed and random effects models. In: Mulrow CD, Oxman AD, editors. Cochrane collaboration handbook, 1998. Cochrane Database Syst Rev 2001;20:3635-47.
34. Greenland S. Invited commentary: a critical took at some popular meta-analytic methods. Am J Epidemiol 1994;140: 290-6.
35. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUORUM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900.
36. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21: 1559-73.
37. Thery C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992;85:1380-9.
38. Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-5.
39. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE study group. Tinzaparine ou heparine standard: evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9.